PMID- 16082401
OWN - NLM
STAT- MEDLINE
DCOM- 20061207
LR  - 20221207
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 20
IP  - 5
DP  - 2006 May
TI  - Review of first year result of photodynamic therapy on age-related macular 
      degeneration in Chinese population.
PG  - 523-6
AB  - PURPOSE: To evaluate the effect of verteporfin therapy (Visudyne) on age-related 
      macular degeneration (AMD) in Chinese patients. The baseline characteristic and 
      the visual outcome will be compared with the treatment of AMD with photodynamic 
      therapy study (TAP) and verteporfin in photodynamic therapy study (VIP). DESIGN: 
      Retrospective comparative case series. METHOD: We recruited patients >50 years 
      old, with best-corrected visual acuity >20/200 and fluorescein angiography 
      documenting subfoveal either predominantly classic with greatest linear dimension 
      <5400 mum or pure occult choroidal neovascularization (CNV) secondary to AMD. We 
      applied non-thermal laser to the lesion 15 min after visudyne infusion as 
      described in TAP study. Patients were followed up with fluorescein angiography 
      every 3 months. Additional treatment would be offered if there was evidence of 
      recurrence of CNV. OUTCOME MEASURE: Baseline characteristic and visual outcome. 
      RESULT: In all, 46 eyes of 42 patients were enrolled at our centre from July 2002 
      to June 2003. They comprised 11 eyes with predominantly classic lesions and 35 
      eyes with pure occult lesion. The mean number of treatment sessions given was 2.9 
      in the first year. At the 12-month examination, there were 63 and 29% of patients 
      showing visual improvement in predominantly classic and occult groups, 
      respectively, while there were only 16% of patients in the TAP study and 12% of 
      patients in the VIP study showing visual improvement in the same period. 
      CONCLUSION: Verteporfin therapy for subfoveal CNV is beneficial to Chinese 
      patients with AMD at first year. The visual result seems to be better than that 
      observed in Caucasian patients.
FAU - Yang, N
AU  - Yang N
AD  - Department of Ophthalmology, Tuen Mun Hospital, HKSAR, Tuen Mun, NT, Hong Kong. 
      nyang8@hotmail.com
FAU - Fan, C M
AU  - Fan CM
FAU - Ho, C K
AU  - Ho CK
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0X9PA28K43 (Verteporfin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Choroidal Neovascularization/drug therapy/ethnology/etiology/physiopathology
MH  - Female
MH  - Humans
MH  - Macular Degeneration/complications/*drug therapy/ethnology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/therapeutic use
MH  - Porphyrins/therapeutic use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Verteporfin
MH  - Visual Acuity
EDAT- 2005/08/06 09:00
MHDA- 2006/12/09 09:00
CRDT- 2005/08/06 09:00
PHST- 2005/08/06 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2005/08/06 09:00 [entrez]
AID - 6701991 [pii]
AID - 10.1038/sj.eye.6701991 [doi]
PST - ppublish
SO  - Eye (Lond). 2006 May;20(5):523-6. doi: 10.1038/sj.eye.6701991.